A selective alternative pathway complement inhibitor for treatment of paroxysmal nocturnal hemoglobinuria
Sülzen, H.; Tulmin, H.; Hajek, M.; Cermak, J.; Kadlecova, A.; Pompach, P.; Votrubova, J.; Zoltner, M.; Zoll, S.
Show abstract
The complement system, a critical component of the human innate immune system, enhances the ability to clear microbes and damaged cells. Dysregulation of this system, particularly the alternative pathway (AP), can lead to several rare blood disorders such as paroxysmal nocturnal hemoglobinuria (PNH). This study introduces SH-01, a blood parasite-derived, novel recombinant protein which selectively inhibits the AP. We show that SH-01 effectively prevents the lysis of erythrocytes isolated from PNH patients. Unlike current treatments such as eculizumab, SH-01 targets the AP without impairing the classical or lectin pathways, reducing the risk of infections and extravascular hemolysis. SH-01 functions through a unique two-stage mechanism, preventing C3b deposition and inhibiting AP C5 convertase activity while maintaining the amplification loops functionality. Immunization studies in mice showed no significant immune response against SH-01, and the protein exhibited high stability and no acute toxicity. These findings suggest SH-01 as a promising candidate for treatment of PNH and other diseases characterized by AP hyperactivation, offering a more targeted therapeutic and thus safer approach.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Opsonization by non-neutralizing antibodies can confer protection to SARS-CoV-2 despite Spike-dependent modulation of phagocytosis 97%
- Molecular Landscape of Anti-Drug Antibodies Reveals the Mechanism of the Immune Response Following Treatment with TNF-alpha Antagonists 96%
- Human Fcγ-receptors selectively respond to C-reactive protein (CRP) isoforms 95%
Similar papers in this journal
- Soluble MAC is primarily released from MAC-resistant bacteria that potently convert complement component C5 95%
- Expression of modified FcγRI enables myeloid cells to elicit robust tumor-specific cytotoxicity 95%
- One N-glycan regulates natural killer cell antibody-dependent cell-mediated cytotoxicity and modulates Fc γ receptor IIIa / CD16a structure 94%
Similar papers in this journal
- Novel rapid high-throughput method of NETosis Induction and Inhibition with physiological triggers and inhibitors 94%
- Comprehensive analysis of platelet glycoprotein Ibα glycosylation. 93%
- Relieving platelet inhibition using a novel bi-specific antibody:A novel approach for circumventing the platelet storage lesion 93%
Similar papers in this journal
- Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodies 97%
- The molecular basis of immunosuppression by soluble CD52 is defined by interactions of N-linked and O-linked glycans with HMGB1 Box B 95%
- Disrupting the CD177:proteinase 3 membrane complex reduces anti-PR3 antibody-induced neutrophil activation 95%
Similar papers in this journal
- A mechanistically novel peptide agonist of the IL-7 receptor that addresses limitations of IL-7 cytokine therapy 95%
- SARS-CoV2 mutant-specific T cells and neutralizing antibodies after vaccination and up to 1 year after infection 95%
- Targeting prostate cancer by new bispecific monocyte engager directed to prostate-specific membrane antigen 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.